ViewPoints Interview: Maxwell Biosciences’ Dr. Gill Diamond and Joshua McClure Share Insights Novel Peptoids with Potent Antiviral Activity Against HSV-1 and SARS-CoV-2
In an interview with PharmaShots, Dr. Gill Diamond, Scientific Advisory Board Member and Joshua McClure, CEO and Co-founder of Maxwell Biosciences share their views on the news findings of the company published in MDI that demonstrated that several peptoids exhibit potent in vitro antiviral activity against both HSV-1 and SARS-CoV-2.
Shots:
The studies showed that antiviral peptoids disrupt the phospholipid envelopes of the viruses by a mechanism like that observed for natural human antiviral peptides
CLAROMER platform compounds are novel oligomers with peptide-like properties called peptidomimetics or more commonly, peptoids. Peptoids possess desirable attributes of both small molecules and peptides but are completely synthetic cationic foldamers
Maxwell is collaborating with scientists and institutions around the world targeting formerly untreatable viruses with product candidates that appear well-tolerated in the infected tissues